Cargando…
Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values
BACKGROUND: Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA is completed through reverse transcriptase-PCR (RT-PCR) from either oropharyngeal or nasopharyngeal swabs, critically important for diagnostics but also from an infection control lens. Recent studies have sugge...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817557/ https://www.ncbi.nlm.nih.gov/pubmed/35123573 http://dx.doi.org/10.1186/s13756-022-01067-1 |
_version_ | 1784645672677408768 |
---|---|
author | Thornton, Christina S. Huntley, Kevin Berenger, Byron M. Bristow, Michael Evans, David H. Fonseca, Kevin Franko, Angela Gillrie, Mark R. Lin, Yi-Chan Povitz, Marcus Shafey, Mona Conly, John M. Tremblay, Alain |
author_facet | Thornton, Christina S. Huntley, Kevin Berenger, Byron M. Bristow, Michael Evans, David H. Fonseca, Kevin Franko, Angela Gillrie, Mark R. Lin, Yi-Chan Povitz, Marcus Shafey, Mona Conly, John M. Tremblay, Alain |
author_sort | Thornton, Christina S. |
collection | PubMed |
description | BACKGROUND: Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA is completed through reverse transcriptase-PCR (RT-PCR) from either oropharyngeal or nasopharyngeal swabs, critically important for diagnostics but also from an infection control lens. Recent studies have suggested that COVID-19 patients can demonstrate prolonged viral shedding with immunosuppression as a key risk factor. CASE PRESENTATION: We present a case of an immunocompromised patient with SARS-CoV-2 infection demonstrating prolonged infectious viral shedding for 189 days with virus cultivability and clinical relapse with an identical strain based on whole genome sequencing, requiring a multi-modal therapeutic approach. We correlated clinical parameters, PCR cycle thresholds and viral culture until eventual resolution. CONCLUSIONS: We successfully demonstrate resolution of viral shedding, administration of COVID-19 vaccination and maintenance of viral clearance. This case highlights implications in the immunosuppressed patient towards infection prevention and control that should consider those with prolonged viral shedding and may require ancillary testing to fully elucidate viral activity. Furthermore, this case raises several stimulating questions around complex COVID-19 patients around the role of steroids, effect of antiviral therapies in absence of B-cells, role for vaccination and the requirement of a multi-modal approach to eventually have successful clearance of the virus. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13756-022-01067-1. |
format | Online Article Text |
id | pubmed-8817557 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88175572022-02-07 Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values Thornton, Christina S. Huntley, Kevin Berenger, Byron M. Bristow, Michael Evans, David H. Fonseca, Kevin Franko, Angela Gillrie, Mark R. Lin, Yi-Chan Povitz, Marcus Shafey, Mona Conly, John M. Tremblay, Alain Antimicrob Resist Infect Control Case Report BACKGROUND: Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA is completed through reverse transcriptase-PCR (RT-PCR) from either oropharyngeal or nasopharyngeal swabs, critically important for diagnostics but also from an infection control lens. Recent studies have suggested that COVID-19 patients can demonstrate prolonged viral shedding with immunosuppression as a key risk factor. CASE PRESENTATION: We present a case of an immunocompromised patient with SARS-CoV-2 infection demonstrating prolonged infectious viral shedding for 189 days with virus cultivability and clinical relapse with an identical strain based on whole genome sequencing, requiring a multi-modal therapeutic approach. We correlated clinical parameters, PCR cycle thresholds and viral culture until eventual resolution. CONCLUSIONS: We successfully demonstrate resolution of viral shedding, administration of COVID-19 vaccination and maintenance of viral clearance. This case highlights implications in the immunosuppressed patient towards infection prevention and control that should consider those with prolonged viral shedding and may require ancillary testing to fully elucidate viral activity. Furthermore, this case raises several stimulating questions around complex COVID-19 patients around the role of steroids, effect of antiviral therapies in absence of B-cells, role for vaccination and the requirement of a multi-modal approach to eventually have successful clearance of the virus. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13756-022-01067-1. BioMed Central 2022-02-05 /pmc/articles/PMC8817557/ /pubmed/35123573 http://dx.doi.org/10.1186/s13756-022-01067-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Thornton, Christina S. Huntley, Kevin Berenger, Byron M. Bristow, Michael Evans, David H. Fonseca, Kevin Franko, Angela Gillrie, Mark R. Lin, Yi-Chan Povitz, Marcus Shafey, Mona Conly, John M. Tremblay, Alain Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values |
title | Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values |
title_full | Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values |
title_fullStr | Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values |
title_full_unstemmed | Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values |
title_short | Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values |
title_sort | prolonged sars-cov-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817557/ https://www.ncbi.nlm.nih.gov/pubmed/35123573 http://dx.doi.org/10.1186/s13756-022-01067-1 |
work_keys_str_mv | AT thorntonchristinas prolongedsarscov2infectionfollowingrituximabtreatmentclinicalcourseandresponsetotherapeuticinterventionscorrelatedwithquantitativeviralculturesandcyclethresholdvalues AT huntleykevin prolongedsarscov2infectionfollowingrituximabtreatmentclinicalcourseandresponsetotherapeuticinterventionscorrelatedwithquantitativeviralculturesandcyclethresholdvalues AT berengerbyronm prolongedsarscov2infectionfollowingrituximabtreatmentclinicalcourseandresponsetotherapeuticinterventionscorrelatedwithquantitativeviralculturesandcyclethresholdvalues AT bristowmichael prolongedsarscov2infectionfollowingrituximabtreatmentclinicalcourseandresponsetotherapeuticinterventionscorrelatedwithquantitativeviralculturesandcyclethresholdvalues AT evansdavidh prolongedsarscov2infectionfollowingrituximabtreatmentclinicalcourseandresponsetotherapeuticinterventionscorrelatedwithquantitativeviralculturesandcyclethresholdvalues AT fonsecakevin prolongedsarscov2infectionfollowingrituximabtreatmentclinicalcourseandresponsetotherapeuticinterventionscorrelatedwithquantitativeviralculturesandcyclethresholdvalues AT frankoangela prolongedsarscov2infectionfollowingrituximabtreatmentclinicalcourseandresponsetotherapeuticinterventionscorrelatedwithquantitativeviralculturesandcyclethresholdvalues AT gillriemarkr prolongedsarscov2infectionfollowingrituximabtreatmentclinicalcourseandresponsetotherapeuticinterventionscorrelatedwithquantitativeviralculturesandcyclethresholdvalues AT linyichan prolongedsarscov2infectionfollowingrituximabtreatmentclinicalcourseandresponsetotherapeuticinterventionscorrelatedwithquantitativeviralculturesandcyclethresholdvalues AT povitzmarcus prolongedsarscov2infectionfollowingrituximabtreatmentclinicalcourseandresponsetotherapeuticinterventionscorrelatedwithquantitativeviralculturesandcyclethresholdvalues AT shafeymona prolongedsarscov2infectionfollowingrituximabtreatmentclinicalcourseandresponsetotherapeuticinterventionscorrelatedwithquantitativeviralculturesandcyclethresholdvalues AT conlyjohnm prolongedsarscov2infectionfollowingrituximabtreatmentclinicalcourseandresponsetotherapeuticinterventionscorrelatedwithquantitativeviralculturesandcyclethresholdvalues AT tremblayalain prolongedsarscov2infectionfollowingrituximabtreatmentclinicalcourseandresponsetotherapeuticinterventionscorrelatedwithquantitativeviralculturesandcyclethresholdvalues |